Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

INSIDE INFORMATION

COMPLETION OF THE H SHARE FULL CIRCULATION

This announcement is made by Medtide Inc. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (i) the announcement of the Company dated July 27, 2025 in relation to the application for the H share full circulation by the Company; and (ii) the announcement of the Company dated February 5, 2026 in relation to the issuance of the Filing Notice by the CSRC for the H share full circulation application of the Company (collectively, the "**Announcements**"). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board of the Company is pleased to announce that the conversion of 68,201,112 Unlisted Shares into H shares had been completed on March 9, 2026, and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on March 10, 2026.

SHAREHOLDING STRUCTURE

The shareholding structure of the Company immediately before and upon the completion of the Conversion and Listing is set out below:

	As at the date of this announcement		Upon completion of the Conversion and Listing	
Class of Shares	**Number of shares**	**Approximate percentage of the total number of issued shares of the Company (%)**	**Number of shares**	**Approximate percentage of the total number of issued shares of the Company (%)**
H shares	73,598,888	51.90%	141,800,000	100.00%
Unlisted shares	68,201,112	48.10%	–	–
Total	**141,800,000**	**100.00%**	**141,800,000**	**100.00%**

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company.

By order of the Board
Medtide Inc.
泰德醫藥(浙江)股份有限公司
Dr. Xu Qi
Chairwoman and Chief Executive Officer

Hong Kong, March 9, 2026

As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉), Ms. Cheng Tao and Ms. Li Lingmei (李玲梅); the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).